The shortage of tirzepatide injection has been resolved after two years of limited availability in the wake of high demand, the FDA said.
Tirzepatide is the active ingredient in Mounjaro, Eli Lilly's diabetes drug, and Zepbound, the company's weight loss medication. While the shortage has passed, patients and prescribers may still encounter intermittent localized supply disruptions as products move through the supply chain, according to a Oct. 2 news release from the agency.
The FDA noted that other GLP-1 medications, including dulaglutide, semaglutide and liraglutide injections, remain in shortage. The agency said it will continue to collaborate with manufacturers to monitor and address ongoing supply issues.